Mesenchymal Stem Cell 1 (MSC1)-Based Therapy Attenuates Tumor Growth Whereas MSC2-Treatment Promotes Tumor Growth and Metastasis

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Waterman, Ruth S ^a   Henkle, Sarah L ^b   Betancourt, Aline M ^b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; COLLAGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL TYPE; COCULTURE; COLLAGEN METABOLISM; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE COUNT; MAST CELL DEGRANULATION; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL 1; MESENCHYMAL STEM CELL 2; MESENCHYMAL STEM CELL TRANSPLANTATION; METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OVARY CARCINOMA; TREATMENT RESPONSE; TUMOR SPHEROID;

CELL DIVISION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; NEOPLASM METASTASIS; NEOPLASMS;

ANIMALIA;

EID: 84866689845     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045590     Document Type: Article

References (49)

1. Salem HK, Thiemermann C, (2010) Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 28: 585-596.
2. Tolar J, Le Blanc K, Keating A, Blazar BR, (2010) Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells 28: 1446-1455.
3. Waterman RS, Betancourt AM (2012) The role of mesenchymal stem cells in the tumor microenvironment: InTech. http://www.intechopen.com/books/tumor-microenvironment-and-myelomonocytic-cells/the-role-of-mesenchymal-stem-cells-in-the-tumor-microenvironment.
4. Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini F 3rd (2010) Dissecting a Discrepancy in the Literature: Do Mesenchymal Stem Cells Support or Suppress Tumor Growth? Stem Cells.
5. Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini F 3rd (2011) Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells 29: 11-19.
6. Kidd S, Spaeth E, Klopp A, Andreeff M, Hall B, et al. (2008) The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe. Cytotherapy 10: 657-667.
7. Coffelt SB, Marini FC, Watson K, Zwezdaryk KJ, Dembinski JL, et al. (2009) The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci U S A 106: 3806-3811.
8. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, et al. (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449: 557-563.
9. Rayment EA, Williams DJ, (2010) Concise review: mind the gap: challenges in characterizing and quantifying cell- and tissue-based therapies for clinical translation. Stem Cells 28: 996-1004.
10. von Bahr L, Batsis I, Moll G, Hagg M, Szakos A, et al. (2012) Analysis of Tissues Following Mesenchymal Stromal Cell Therapy in Humans Indicate Limited Long-Term Engraftment and No Ectopic Tissue Formation. Stem Cells.
11. Coffelt SB, Scandurro AB, (2008) Tumors sound the alarmin(s). Cancer Res 68: 6482-6485.
12. Zwezdaryk KJ, Coffelt SB, Figueroa YG, Liu J, Phinney DG, et al. (2007) Erythropoietin, a hypoxia-regulated factor, elicits a pro-angiogenic program in human mesenchymal stem cells. Exp Hematol 35: 640-652.
13. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM, (2010) A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One 5: e10088.
14. Waterman RS, Jenny M, Bobby DN, Anna ES, Aline MB (2012) Anti-Inflammatory Mesenchymal Stem Cells (MSC2) Attenuate Symptoms of Painful Diabetic Peripheral Neuropathy. Stem Cells Translational Medicine: 557-565.
15. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A, (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555.
16. Martinez FO, Gordon S, Locati M, Mantovani A, (2006) Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 177: 7303-7311.
17. Mosser DM, Zhang X (2008) Activation of murine macrophages. Curr Protoc Immunol Chapter 14: Unit 14 12.
18. Mosser DM, Edwards JP, (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958-969.
19. Mantovani A, Sica A, Locati M, (2007) New vistas on macrophage differentiation and activation. Eur J Immunol 37: 14-16.
20. Coffelt SB, Tomchuck SL, Zwezdaryk KJ, Danka ES, Scandurro AB, (2009) Leucine leucine-37 uses formyl peptide receptor-like 1 to activate signal transduction pathways, stimulate oncogenic gene expression, and enhance the invasiveness of ovarian cancer cells. Mol Cancer Res 7: 907-915.
21. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, et al. (2000) Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21: 585-591.
22. Ribatti D, Nico B, Finato N, Crivellato E, (2011) Tryptase-positive mast cells and CD8-positive T cells in human endometrial cancer. Pathol Int 61: 442-444.
23. Murdoch C, Muthana M, Coffelt SB, Lewis CE, (2008) The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8: 618-631.
24. Navi D, Saegusa J, Liu FT, (2007) Mast cells and immunological skin diseases. Clin Rev Allergy Immunol 33: 144-155.
25. Brown JM, Nemeth K, Kushnir-Sukhov NM, Metcalfe DD, Mezey E, (2011) Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism. Clin Exp Allergy 41: 526-534.
26. Bianchi G, Borgonovo G, Pistoia V, Raffaghello L, (2011) Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells. Histol Histopathol 26: 941-951.
27. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, et al. (2003) Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102: 3837-3844.
28. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, et al. (2006) Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 203: 1235-1247.
29. Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Kodama M, et al. (2010) Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer 127: 2323-2333.
30. Gialeli C, Theocharis AD, Karamanos NK, (2010) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278: 16-27.
31. Cubillos-Ruiz JR, Rutkowski M, Conejo-Garcia JR, (2010) Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. Cell Cycle 9: 260-268.
32. Nesbeth Y, Scarlett U, Cubillos-Ruiz J, Martinez D, Engle X, et al. (2009) CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion. Cancer Res 69: 6331-6338.
33. Prockop DJ, Youn Oh J (2011) Mesenchymal Stem/Stromal Cells (MSCs): Role as Guardians of Inflammation. Mol Ther.
34. Singer NG, Caplan AI, (2011) Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol 6: 457-478.
35. Condeelis J, Pollard JW, (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124: 263-266.
36. Baay M, Brouwer A, Pauwels P, Peeters M, Lardon F, (2011) Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy. Clin Dev Immunol 2011: 565187.
37. Sica A, Bronte V, (2007) Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155-1166.
38. Ingman WV, Wyckoff J, Gouon-Evans V, Condeelis J, Pollard JW, (2006) Macrophages promote collagen fibrillogenesis around terminal end buds of the developing mammary gland. Dev Dyn 235: 3222-3229.
39. Coffelt SB, Hughes R, Lewis CE, (2009) Tumor-associated macrophages: Effectors of angiogenesis and tumor progression. Biochim Biophys Acta 1796: 11-18.
40. Coussens LM, Werb Z, (2002) Inflammation and cancer. Nature 420: 860-867.
41. Fidler IJ, (2003) The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458.
42. Rabinovich GA, Gabrilovich D, Sotomayor EM, (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25: 267-296.
43. Strausberg RL, (2005) Tumor microenvironments, the immune system and cancer survival. Genome Biol 6: 211.
44. Mason C, Brindley DA, Culme-Seymour EJ, Davie NL, (2011) Cell therapy industry: billion dollar global business with unlimited potential. Regen Med 6: 265-272.
45. Tomchuck SL, Zwezdaryk KJ, Coffelt SB, Waterman RS, Danka ES, et al. (2008) Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 26: 99-107.
46. Liu Y, Zeng B, Zhang Z, Zhang Y, Yang R, (2008) B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer. Clin Immunol 129: 471-481.
47. Ohtaki H, Ylostalo JH, Foraker JE, Robinson AP, Reger RL, et al. (2008) Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses. Proc Natl Acad Sci U S A 105: 14638-14643.
48. Yang R, Cai Z, Zhang Y, Yutzy WH, Roby KF, et al. (2006) CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res 66: 6807-6815.
49. Coffelt SB, Waterman RS, Florez L, Honer zu Bentrup K, Zwezdaryk KJ, et al. (2008) Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. Int J Cancer 122: 1030-1039.